# Effect of CT1812 Treatment on Brain Synaptic Density

> **NCT03493282** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cognition Therapeutics** · enrollment: 43 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Active Treatment- CT1812 100 mg
- **DRUG:** Active Treatment- CT1812 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03493282
- **Lead sponsor:** Cognition Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2020-10-16
- **Final completion:** 2020-10-16
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493282, "Effect of CT1812 Treatment on Brain Synaptic Density". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03493282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*